




Listing of Claims

1 - 21. (CANCELLED)

- 5 22. (CURRENTLY AMENDED) A compound of formula (Ia) (or a salt or ester, or salt of an ester, thereof):




(Ia)

wherein

- 10 R^A is M_x -aryl or M_x -heterocycle where M is a substituted or unsubstituted methylene, x is an integer from 1 to 6, the aryl moiety may bear one or more substituents, and the heterocycle is a substituted or unsubstituted, aromatic or nonaromatic heterocyclic moiety comprising a 5- to 7-membered ring bearing one or more heteroatoms;

R^B comprises an aryl, or heteroaryl moiety bearing at least one a substituent of

- 15 Series IIb:



IIb

- 20 R^C is hydrogen, halogen, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or -ZR, wherein Z is -O-, -S-, or NR, wherein each occurrence of R without a further alphanumeric superscript is independently hydrogen, or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

- 25 each occurrence of K is independently -O- or -S-;

each occurrence of Y is independently -O-, -S-, -NR- or a chemical bond;

each occurrence of R (without a further alphanumeric superscript) is independently hydrogen, or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

5

each occurrence of R¹ is independently a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or, except in YR¹ moieties in which Y is a covalent bond, R¹ may also be H;

10

each occurrence of R² is independently R¹, -PK(YR¹)(YR¹), -SO₂(YR¹) or -C(O)(YR¹);

each occurrence of R⁶ independently represents an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

15

each occurrence of G is independently -O-, -S-, -NR- or M_x; and,

each occurrence of MY is independently a methine group or a lower alkyl moiety which contains a methine group and optionally may be further substituted.

20

wherein in each of the foregoing groups each aliphatic or heteroaliphatic moiety may be branched or unbranched, cyclic or acyclic and substituted or unsubstituted, and each aryl and heteroaryl moiety may be substituted or unsubstituted.

25

23. (PREVIOUSLY PRESENTED) The compound of claim 22 wherein M_x is methylene, ethylene or propylene, and the aryl moiety is o-, m-, or p-hydroxy-, 2,3-dihydroxy-, 2,4-dihydroxy-, 2,5-dihydroxy-, 3,4-dihydroxy-, or 3,5-dihydroxyphenyl.

30

24. (PREVIOUSLY PRESENTED) The compound of claim 22, wherein R^C is -OR, where R is H, aliphatic, heteroaliphatic, aryl, or heteroaryl.

35


25. (PREVIOUSLY PRESENTED) The compound of claim 22, wherein R^C is -R, -NRR or -OR in which each R is C1-C8 aliphatic, which may be branched or unbranched, cyclic or noncyclic, and which may be substituted with one or more hydroxy, alkoxy, aralkoxy, carbamyl, amino, substituted amino, cyano, halogen, nitro or sulfo groups, and/or with one

or more alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, aryloxy or aralkyl moieties which may themselves be substituted with one or more hydroxy, alkoxy, aralkoxy, carbamyl, amino, substituted amino, cyano, halogen, nitro or sulfo groups.

- 5 26. (PREVIOUSLY PRESENTED) The compound of claim 25, wherein each said R comprises a C1-C8 aliphatic moiety substituted with one or more groups selected from the following: a substituted or unsubstituted amine or 5- to 7-membered heterocyclic moiety, which may itself be optionally substituted.


10 27 - 28. (CANCELLED)

29. (PREVIOUSLY PRESENTED) The compound of any of claims 22, 23, 24, 25, 26, 47 or 48 in which R^B comprises




- 15 wherein each R¹ is independently H, alkyl, arylalkyl, or aryl.

30. (PREVIOUSLY PRESENTED) The compound of any of claims 22, 23, 24, 25, 26, 47 or 48 in which R^B comprises



- 20 wherein each R⁶ is independently alkyl, arylalkyl, or aryl.


31. (PREVIOUSLY PRESENTED) The compound of any of claims 22, 23, 24, 25, 26, 47 or 48 in which R^B comprises



- 25 wherein R¹ is H, alkyl, or arylalkyl and R⁶ is aliphatic, heteroaliphatic, aryl, or heteroaryl.

32. (PREVIOUSLY PRESENTED)
or 48 in which R^B comprises

The compound of any of claims 22, 23, 24, 25, 26, 47




wherein each R⁶ is independently aliphatic, heteroaliphatic, aryl, or heteroaryl.

5

33. (PREVIOUSLY PRESENTED)
which R^B comprises


The compound of any of claims 22, 23, 24, 25, 26, 47 or 48 in



10 wherein each R¹ is H, alkyl, or arylalkyl.

34. (PREVIOUSLY PRESENTED)
which R^B comprises

The compound of any of claims 22, 23, 24, 25, 26, 47 or 48 in




15

wherein each R¹ is independently H, alkyl, arylalkyl, or aryl and R is aliphatic, heteroaliphatic, aryl, or heteroaryl.

20 35. (CANCELLED)

36. (CURRENTLY AMENDED) A compound of formula (Ib) (or a salt or ester, or salt of an ester, thereof):



(Ib)


wherein

R^A is hydrogen, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

R^C is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;


R^D is hydrogen, halogen, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or -
 10 ZR; wherein Z is -O-, -S-, or NR, wherein each occurrence of R without a further
 alphanumeric superscript is independently hydrogen, or a substituted or unsubstituted
 aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

R^8 is selected from the moieties of Series II:




II

or



is selected from the moieties of Series III:



III

R³ represents from 0-3 substituents independently selected from the group consisting of halogen, R, -GR, -CO(YR), amido, amidino, cyano, nitro, azido, ~~sulfate~~, sulfamoyl, sulfonamido, and substituents of Series II;

M is a substituted or unsubstituted methylene; x is an integer from 1 to 6;

each occurrence of K is independently -O- or -S-;

each occurrence of Y is independently -O-, -S-, -NR- or a chemical bond;

each occurrence of R¹ is independently a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or, except in YR¹ moieties in which Y is a covalent bond, R¹ may also be H;

each occurrence of R² is independently R¹, -PK(YR¹)(YR¹), -SO₂(YR¹) or -C(O)(YR¹)

each occurrence of G is independently -O-, -S-, -NR- or M_x; and,

each occurrence of My is independently a methine group or a lower alkyl moiety which contains a methine group and optionally may be further substituted;

wherein in each of the foregoing groups each aliphatic or heteroaliphatic moiety may be branched or unbranched, cyclic or acyclic and substituted or unsubstituted, and each aryl and heteroaryl moiety may be substituted or unsubstituted;

5 with the following provisos:

(1) R^D is a moiety other than one comprising a substituted or unsubstituted arylene moiety (in which up to two methine carbons may be replaced by nitrogen atoms), a C3-7 cycloalkylene moiety (which may contain nitrogen atoms in place of up to two ring carbons),
10 an indanylene moiety, or a 1,2,3,4-tetrahydronaphthylene moiety;


(2) R^D is a moiety other than one bearing a cyano group or an N-substituted or unsubstituted amino, amidino, guanidino or guanidinoalkyl group;

15 R^C is covalently attached through a C-C bond to the carbon atom at ring position 2 of the purine ring system.

37 and 38. (CANCELLED)

20

39. (PREVIOUSLY PRESENTED) The compound (or a salt or ester, or salt of an ester, thereof) of the formula :



wherein

25 R^A is hydrogen, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

R^C is hydrogen, halogen, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or -ZR, wherein Z is -O-, -S-, or NR, wherein each occurrence of R without a further alphanumeric superscript is independently hydrogen, or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

R^D is hydrogen, halogen, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or -Z R , with the proviso that R^D does not bear a cyano group or an N-substituted or unsubstituted amino, amidino, guanidino or guanidinoalkyl group;

each R^6 is independently aliphatic, heteroaliphatic, aryl, or heteroaryl and
5 wherein in each of the foregoing groups each aliphatic or heteroaliphatic moiety may be branched or unbranched, cyclic or acyclic and substituted or unsubstituted, and each aryl and heteroaryl moiety may be substituted or unsubstituted.

40. (PREVIOUSLY PRESENTED) A composition containing a compound of any of claims 22, 23,
10 24, 25, 26, 29, 30, 31, 32, 33, 34, 36, 39, 47, 48, 49, 50 or 51, and one or more pharmaceutically acceptable excipients or additives.

41 - 46. (CANCELLED)

15 47. (PREVIOUSLY PRESENTED) The compound of claim 23, wherein R^C is -R, -NRR or -OR in which each R is C1-C8 aliphatic, which may be branched or unbranched, cyclic or noncyclic, and which may be substituted with one or more hydroxy, alkoxy, aralkoxy, carbamyl, amino, substituted amino, cyano, halogen, nitro or sulfo groups, and/or with one or more alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, aryloxy or aralkyl moieties which
20 may themselves be substituted with one or more hydroxy, alkoxy, aralkoxy, carbamyl, amino, substituted amino, cyano, halogen, nitro or sulfo groups.

48. (PREVIOUSLY PRESENTED) The compound of claim 47, wherein each said R comprises a C1-C8 aliphatic moiety substituted with one or more groups selected from the following: a
25 substituted or unsubstituted amine or 5- to 7-membered heterocyclic moiety, which may itself be optionally substituted.

49. (PREVIOUSLY PRESENTED) The compound of claim 39 in which R^D is H or halo.

30 50 (PREVIOUSLY PRESENTED). The compound of claim 39 wherein R^C is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety which is covalently attached through a carbon-carbon bond to the carbon atom at ring position 2 of the purine ring system.

51 (PREVIOUSLY PRESENTED). The compound of claim 50 in which R^D is H.

35 52 (PREVIOUSLY PRESENTED). The compound of claim 51 in which R^D is F.